Literature DB >> 8168112

Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme.

R S Morrison1, F Yamaguchi, J M Bruner, M Tang, W McKeehan, M S Berger.   

Abstract

Glioblastomas were examined for abnormalities in fibroblast growth factor receptor (FGFR) expression by polymerase chain reaction and immunocytochemical analysis. Polymerase chain reaction analysis demonstrated that FGFR1 mRNA levels were significantly higher in glioblastomas than in normal brain adjacent to the tumor or in untransformed human brain. These results were consistent with immunocytochemical localization of FGFR1 protein in glioblastomas: glioblastoma cells exhibited intense FGFR1 immunoreactivity in frozen sections of tumor and low to undetectable FGFR1 immunoreactivity in adjacent normal brain or in normal white matter obtained from patients without neoplastic disease. Endothelial cells of capillaries and larger vessels within the tumor were devoid of FGFR1 immunoreactivity. All glioblastomas evaluated in the present study expressed FGFR1 mRNA and FGFR1 immunoreactivity. Examination of the FGFR1 gene by Southern blot analysis indicated that overexpression of FGFR1 mRNA in glioblastomas did not result from gene amplification. These results indicate that glioblastoma cells, in contrast to endothelial cells within the tumor, display increased levels of FGFR1. Therefore, FGFR1 signal transduction may be associated with increased autocrine growth activity of tumor cells and is probably not related to the increased endothelial cell proliferation associated with these tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168112

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.

Authors:  Chengkai Dai; Yelena Lyustikman; Alan Shih; Xiaoyi Hu; Gregory N Fuller; Marc Rosenblum; Eric C Holland
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 2.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 3.  Angiogenic growth factors in neural embryogenesis and neoplasia.

Authors:  D Zagzag
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 4.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Ashok Godavarthi; Raghu Chandrashekar
Journal:  Med Oncol       Date:  2017-09-26       Impact factor: 3.064

Review 6.  Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs.

Authors:  I F Dunn; O Heese; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 7.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  Progress on antiangiogenic therapy for patients with malignant glioma.

Authors:  Manmeet S Ahluwalia; Candece L Gladson
Journal:  J Oncol       Date:  2010-04-06       Impact factor: 4.375

10.  Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth.

Authors:  Changliang Shan; Hee-Bum Kang; Shannon Elf; Jianxin Xie; Ting-Lei Gu; Mike Aguiar; Scott Lonning; Taro Hitosugi; Tae-Wook Chung; Martha Arellano; Hanna J Khoury; Dong M Shin; Fadlo R Khuri; Titus J Boggon; Jun Fan
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.